Currently, the company sits on a 27-acre lot, and manufactures drugs at its 127,000-sf plant in a quantity only large enough for testing purposes. With the new facility, Human Genome Sciences will produce novel human hormones and proteins, as well as human antibody drugs. "We appreciate the strong support of the financial community which has enabled Human Genome Sciences to finance this important expansion," says company Senior Vice President Steven C. Mayer.

Gilbane Building Company is leading the construction effort and expects to complete the 360,000-sf development half way through 2003. Just four months ago, Human Genome Sciences began construction on another structure, which will be nearly 420,000-sf in size.